Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection

Journal of Controlled Release

Volumn 92, Issue 3, 2003, Pages 265-273

  Wong, Jonathan P ^a   Yang, Huiming ^a   Blasetti, Karen L ^b   Schnell, Glen ^a   Conley, John ^b   Schofield, Lawrence N ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^b Scilab Inc   (Canada)

Author keywords

Ciprofloxacin; Delivery; Efficacy; Liposome; Tularemia

Indexed keywords

AEROSOLS; LIPIDS; PULMONARY DISEASES; RADIOACTIVE TRACERS;

DRUG RETENTION; LIPOSOME ENCAPSULATION;

CONTROLLED DRUG DELIVERY;

AMMONIUM SULFATE; CARBON 14; CHOLESTEROL; CIPROFLOXACIN; LIPOSOME; PHOSPHATIDYLCHOLINE; TRACER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG LIVER LEVEL; DRUG RETENTION; ENCAPSULATION; FEMALE; FRANCISELLA TULARENSIS; INFECTION PREVENTION; LOWER RESPIRATORY TRACT; MOUSE; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; FEMALE; FRANCISELLA TULARENSIS; INJECTIONS, INTRAVENOUS; LIPOSOMES; LIVER; LUNG; MICE; MICE, INBRED BALB C; SPLEEN; SURVIVAL RATE; TISSUE DISTRIBUTION; TULAREMIA;

EID: 1642313902     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(03)00358-4     Document Type: Article

References (31)

1. al-Orainey I.O., Bashandi A.M., Saeed E.N. Failure of ciprofloxacin to eradicate brucellosis in experimental animals. J. Chemother. 2:1990;380-383.
2. Donowitz G.R. Tissue directed antibiotics and intracellular parasites: complex interactions of phagocytes, pathogens and drugs. Clin. Infect. Dis. 19:1994;926-930.
3. Holmes B., Quie P.G., Windhorst D.B., Pollara B., Good R.A. Protection of phagocytized bacteria from the killing action of antibiotics. Nature. 11:1966;1131-1133.
4. Raoult M.M. Optimum treatment of intracellular infection. Drugs. 52:1996;45-59.
5. Rous P., Jones F.S. The protection of pathogenic microorganisms by living tissue cells. J. Exp. Med. 23:1916;601-605.
6. van den Broek P.J. Antimicrobial drugs, microorganisms, and phagocytes. Rev. Infect. Dis. 11:1989;213-245.
7. Nix D.E., Goodwin D., Peloquin C.A., Rotella D.L., Schentag J.J. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob. Agents Chemother. 35:1991;1947-1950.
8. Dalhoff A. A review of quinolone pharmacokinetics. Fernandes P.B. Telesymposium on Quinolones. 1989;277-312 J.R. Prous Science Publishers, Barcelona, Spain.
9. Bergan T., Dalhoff A., Rohwedder R. Pharmacokinetics of ciprofloxacin. Infection. 16(Suppl. 1):1988;3-13.
10. Kuhlmann J., Schaefer H.G., Beermann D. Clinical pharmacology. Kuhlmann J., Dalhoff A., Zeiler H.J. Quinolone Antibacterials. Handbook of Experimental Pharmacology. vol. 127:1998;339-406 Springer-Verlag, Berlin.
11. Easmon C.S.F., Crane J.P. Uptake of ciprofloxacin by macrophages. J. Clin. Pathol. 38:1985;442-444.
12. Easmon C.C.F., Crane J.P. Uptake of ciprofloxacin by human neutrophils. J. Antimicrob. Chemother. 16:1985;67-73.
13. 37Rv multiplying in the J 775 macrophage cell line. Zbl. Bakt. 273:1990;195-199.
14. Hanan M.S., Riad E.M., el Khouly N.A. Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. Dtsch. Tierarztl. Wochenschr. 107:2000;151-155.
15. Eduardo L., Bermudez M., Wu M., Young L.S. Intracellular killing of Mycobacterium avium complex by rifapentine and liposome encapsulated amikacin. J. Infect. Dis. 156:1987;510-513.
16. Nightinghale S.D., Saletan S.L., Swenson C.E., Lawrence A.J., Watson D.A., Pilkiewicz F.G., Silverman E.G., Cal S.X. Liposome encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients. Antimicrob. Agents Chemother. 37:1993;1869-1872.
17. Fountain M.W., Weiss S.J., Fountain A.G., Shen A., Lenk R.P. Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides. J. Infect. Dis. 152:1985;529-535.
18. Majumdar S., Flasher D., Friend D.S., Nassos P., Yajko D., Hadley W.K., Duzgunes N. Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages. Antimicrob. Agents Chemother. 36:1992;2808-2815.
19. D.T. Dennis, T.V. Inglesby, D.A. Henderson, J.G. Bartlett, M.S. Ascher, E. Eitzen, A.D. Fine, A.M. Friedlander, J. Hauer, M. Layton, S.R. Lillibridge, J.E. McDade, M.T. Osterholm, T. O'Toole, G. Parker, T.M. Perl, P.K. Russell, K. Tonat, Tularemia as a biological weapon: medical and public health management, JAMA 285, (2001) 2763-2773.
20. Fortier A.H., Slayter M.V., Ziemba R., Meltzer M.S., Nacy C.A. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect. Immun. 59:1991;2922-2928.
21. Enderlin G., Morales L., Jacobs R.F., Cross L.T. Streptomycin and alternative agents for the treatment of tularaemia; review of literature. Clin. Infect. Dis. 19:1994;42-47.
22. Russell P., Eley S.M., Fulop M.J., Bell D.L., Titball R.W. The efficacy of ciprofloxacin and doxycycline against experimental tularaemia. J. Antimicrob. Chemother. 41:1998;461-465.
23. Oh Y.-K., Nix D.E., Straubinger R.B. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob. Agents Chemother. 39:1995;2104-2111.
24. Conley J., Yang H., Wilson T., Blasetti K., Di Ninno V., Schnell G., Wong J.P. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francsella tularensis infection in mice. Antimicrob. Agents Chemother. 41:1997;1288-1292.
25. Nadithe V., Rahamatalla M., Finlay W.H., Mercer J.R., Samuel J. Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs. J. Pharm. Sci. 92:2003;1066-1076.
26. Wise R., Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur. Respir. J. 14:1999;221-229.
27. Finlay W.H., Wong J.P. Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin. Int. J. Pharm. 167:1998;121-127.
28. Wong J.P., Cherwonogrodzky J.W., Di Ninno V.L., Dela Cruz R., Saravolac E.G. Liposome-encapsulated ciprofloxacin for the prevention and treatment of infectious diseases caused by intracellular pathogens. Shek P.N. Liposomes in Biomedical Applications. 1995;105-120 Harwood Acad. Press, Amsterdam, Holland.
29. Magallanes M., Dijkstra J., Fierer J. Liposome-encapsulated ciprofloxacin in the treatment of murine salmonellosis. Antimicrob. Agents Chemother. 37:1993;2293-2297.
30. Ellbogen M.H., Olsen K.M., Gentry-Nielsen M.J., Preheim L.C. Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J. Antimicrob. Chemother. 51:2003;83-91.
31. Wong J.P., Schnell G., Simpson M., Saravolac E. Effect of liposome-encapsulated ciprofloxacin on phagocytosis, nitric oxide and intracellular killing of Staphylococcus aureus by murine macrophages. Artific. Cells Blood Substit. Immobil. Biotechnol. 28:2000;415-428.